Dementia Today.net

Site updated at Wednesday, 22 June 2016

Living with Dementia

Gammagard

Promising Alzheimer’s Drug Fails in Study

Baxter International Inc. says that a blood product it was testing failed to slow mental decline or to preserve physical function in a major study of 390 patients with mild to moderate Alzheimer’s disease.

The company says that people who received 18 months of infusions with its drug, Gammagard, fared no better than others… Promising Alzheimer’s Drug Fails in Study   



Alzheimer’s Disease

type 1 diabetes1 - risk factors1 - dopamine-producing nerve cells1 - functional imaging1 - management of dementia1 - atherosclerotic plaques2 - depressive pseudodementia1 - mediterranean and dash1 - social support1 - early alzheimer's3 - development of parkinson's1 - prostate cancer1 - blood pressure6 - vesanic dementia2 - substantial hippocampal atrophy1 - insulin-like growth factor-11 - parkinsons disease10 - decline of memory1 - risk of developing parkinson's1 - diet control1 - stiffness2 - problems with memory1 - diabetes10 - non-familial parkinson's1 - giant unilamellar vesicles1 - rheumatoid arthritis1 - sage test1 - developing dementia2 - dementia incident1 - dopamine-deficient worms1 -